**PILOT PHASE**

- n=5 patients affected by PSP

**PRE-TREATMENT ASSESSMENT:**
Motor, neuropsychological and neuroimaging assessments

**BONE MARROW COLLECTION**

**MESENCHYMAL CELL PRODUCTION**

- n=5 patients (arteriography + MSC)

8 weeks FOLLOW-UP ASSESSMENT:
Cell administration safety + motor, neuropsychological and neuroimaging assessments

12 MONTH FOLLOW-UP ASSESSMENT:
Safety. Motor, neuropsychological and neuroimaging assessments

18 MONTH FOLLOW-UP ASSESSMENT:
Safety. Motor, neuropsychological and neuroimaging assessments

---

**RANDOMIZED STUDY**

- n=20 patients affected by PSP

**PRE-TREATMENT ASSESSMENT:**
Motor, neuropsychological and neuroimaging assessments

**BONE MARROW COLLECTION**

**MESENCHYMAL CELL PRODUCTION**

- n=10 patients 1st intervention (arteriography + MSC)
- n=10 patients 1st intervention (sham procedure)

6 MONTH FOLLOW-UP ASSESSMENT:
Safety. Motor, neuropsychological and neuroimaging assessments

- n=10 patients 2nd intervention (sham procedure)
- n=10 patients 2nd intervention (arteriography + MSC)

12 MONTH FOLLOW-UP ASSESSMENT:
Safety. Motor, neuropsychological and neuroimaging assessments.

18 MONTH FOLLOW-UP ASSESSMENT:
Safety. Motor, neuropsychological and neuroimaging assessments.